Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cline Scientific AB ("Cline" or "The Company") today announces it has submitted an international PCT patent application related to the CellRACE cancer diagnostic project.
This application is an extension to the patent application submitted to the European Patent Office, EPO announced on the 11th of March 2021.
"CellRACE is a groundbreaking method and product in cancer diagnostics. It will simplify the choice of treatment by determining the migration potential of tumor cells earlier and more accurately. This reduces the risk of metastasis development in patients. The PCT application is the next step in establishing strong patent protection for the product developed by Cline, an important asset for the project." Says Dr. Hanne Evenbratt, Vice President - Research & Development.
After the PCT phase, the patent will enter national phases where Cline will designate the countries where Cline will pursue patents.
More about the PCT process
The PCT is an international treaty with more than 150 Contracting States, allowing applicants to file for protection in many countries simultaneously with the same filing date. A PCT, or international, application is a unified patent procedure where an application is filed with a Receiving Office, where an international search report and patentability opinion is then conducted. The PCT does not lead to a patent in itself; it is followed by designating which countries the application wants the patent to be examined. In this "national" phase, each jurisdiction designated assesses the applications and grants the patent.
For more information, please contact:
Hanne Evenbratt, VP Research & Development
Email: hanne.evenbratt@clinescientific.com
Phone: +46 704 88 79 23